AIMS/HYPOTHESIS: The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) is an important gene regulator in glucose and lipid metabolism. Unfortunately, PPARγ-activating drugs of the thiazolidinedione class provoke adverse side effects. As recently shown, amorfrutin A1 is a natural glucose-lowering compound that selectively modulates PPARγ. In this study we aimed to characterise, in vitro, a large spectrum of the amorfrutins and similar molecules, which we isolated from various plants. We further studied in vivo the glucose-lowering effects of the so far undescribed amorfrutin B, which featured the most striking PPARγ-binding and pharmacological properties of this family of plant metabolites. METHODS: Amorfrutins were investigated in vitro by binding and cofactor recruitment assays and by transcriptional activation assays in primary human adipocytes and murine preosteoblasts, as well as in vivo using insulin-resistant high-fat-diet-fed C57BL/6 mice treated for 27 days with 100 mg kg(-1) day(-1) amorfrutin B. RESULTS: Amorfrutin B showed low nanomolar binding affinity to PPARγ, and micromolar binding to the isotypes PPARα and PPARβ/δ. Amorfrutin B selectively modulated PPARγ activity at low nanomolar concentrations. In insulin-resistant mice, amorfrutin B considerably improved insulin sensitivity, glucose tolerance and blood lipid variables after several days of treatment. Amorfrutin B treatment did not induce weight gain and furthermore showed liver-protecting properties. Additionally, amorfrutins had no adverse effects on osteoblastogenesis and fluid retention. CONCLUSIONS/ INTERPRETATION: The application of plant-derived amorfrutins or synthetic analogues thereof constitutes a promising approach to prevent or treat complex metabolic diseases such as insulin resistance or type 2 diabetes.
AIMS/HYPOTHESIS: The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) is an important gene regulator in glucose and lipid metabolism. Unfortunately, PPARγ-activating drugs of the thiazolidinedione class provoke adverse side effects. As recently shown, amorfrutin A1 is a natural glucose-lowering compound that selectively modulates PPARγ. In this study we aimed to characterise, in vitro, a large spectrum of the amorfrutins and similar molecules, which we isolated from various plants. We further studied in vivo the glucose-lowering effects of the so far undescribed amorfrutin B, which featured the most striking PPARγ-binding and pharmacological properties of this family of plant metabolites. METHODS: Amorfrutins were investigated in vitro by binding and cofactor recruitment assays and by transcriptional activation assays in primary human adipocytes and murine preosteoblasts, as well as in vivo using insulin-resistant high-fat-diet-fed C57BL/6 mice treated for 27 days with 100 mg kg(-1) day(-1) amorfrutin B. RESULTS:Amorfrutin B showed low nanomolar binding affinity to PPARγ, and micromolar binding to the isotypes PPARα and PPARβ/δ. Amorfrutin B selectively modulated PPARγ activity at low nanomolar concentrations. In insulin-resistant mice, amorfrutin B considerably improved insulin sensitivity, glucose tolerance and blood lipid variables after several days of treatment. Amorfrutin B treatment did not induce weight gain and furthermore showed liver-protecting properties. Additionally, amorfrutins had no adverse effects on osteoblastogenesis and fluid retention. CONCLUSIONS/ INTERPRETATION: The application of plant-derived amorfrutins or synthetic analogues thereof constitutes a promising approach to prevent or treat complex metabolic diseases such as insulin resistance or type 2 diabetes.
Authors: Matthias H Tschöp; John R Speakman; Jonathan R S Arch; Johan Auwerx; Jens C Brüning; Lawrence Chan; Robert H Eckel; Robert V Farese; Jose E Galgani; Catherine Hambly; Mark A Herman; Tamas L Horvath; Barbara B Kahn; Sara C Kozma; Eleftheria Maratos-Flier; Timo D Müller; Heike Münzberg; Paul T Pfluger; Leona Plum; Marc L Reitman; Kamal Rahmouni; Gerald I Shulman; George Thomas; C Ronald Kahn; Eric Ravussin Journal: Nat Methods Date: 2011-12-28 Impact factor: 28.547
Authors: Christopher Weidner; Jens C de Groot; Aman Prasad; Anja Freiwald; Claudia Quedenau; Magdalena Kliem; Annabell Witzke; Vitam Kodelja; Chung-Ting Han; Sascha Giegold; Matthias Baumann; Bert Klebl; Karsten Siems; Lutz Müller-Kuhrt; Annette Schürmann; Rita Schüler; Andreas F H Pfeiffer; Frank C Schroeder; Konrad Büssow; Sascha Sauer Journal: Proc Natl Acad Sci U S A Date: 2012-04-16 Impact factor: 11.205
Authors: Paul A Dutchak; Takeshi Katafuchi; Angie L Bookout; Jang Hyun Choi; Ruth T Yu; David J Mangelsdorf; Steven A Kliewer Journal: Cell Date: 2012-02-03 Impact factor: 41.582
Authors: Diego S Coutinho; Edna A Anjos-Valotta; Caio V M F do Nascimento; Ana Lucia A Pires; Marcelo H Napimoga; Vinícius F Carvalho; Rafael C Torres; Patrícia M R E Silva; Marco A Martins Journal: Front Immunol Date: 2017-06-30 Impact factor: 7.561
Authors: Lakshman Sodagam; Anna Lewinska; Ewa Kwasniewicz; Sofiya Kokhanovska; Maciej Wnuk; Karsten Siems; Suresh I S Rattan Journal: Front Genet Date: 2019-02-21 Impact factor: 4.599
Authors: Limei Wang; Birgit Waltenberger; Eva-Maria Pferschy-Wenzig; Martina Blunder; Xin Liu; Clemens Malainer; Tina Blazevic; Stefan Schwaiger; Judith M Rollinger; Elke H Heiss; Daniela Schuster; Brigitte Kopp; Rudolf Bauer; Hermann Stuppner; Verena M Dirsch; Atanas G Atanasov Journal: Biochem Pharmacol Date: 2014-07-30 Impact factor: 5.858